Pharmacy & Therapeutics - May 2008 - (Page 303) DRUG FORECAST continued from page 281 31. with mild essential hypertension. J Hyper tens 1995;13:1823–1826. Chan DC, Watts GF, Barrett HR, et al. Effect of atorvastatin and fish oil on plasma high sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002;48: 877–963. Nilson DWT, Albrelasen G, Landmark K, et al. Effects of a highdose concentration of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001;74:50–56. Eritsland L, Arnesen H, Gronseth K, et al. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996;77:31–36. Johansen O, Brekke M, Seljeflot I, et al., Coronary Angioplasty Restenosis Trial. n-3 fatty acids do not prevent restenosis after coronary angioplasty: Results from the CART study. J Am Coll Cardiol 1999; 33:1619–1626. The GISSI–Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISS–Prevenzione trial. Lancet 1999;354: 447–455. Bucher HC, Hengstler P, Schindler C, Meier G. n-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials. Am J Med 2002;112:298–304. Studer M, Briel M, Leimensoll B, et al. Effects of different antilipidemic agents and diets on mortality. Arch Intern Med 2005; 165:725–730. Hooper L, Thompson RL, Harrison RA, et al. Omega-3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2006. Issue 2. von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care 2007;10:129–135. McKenney JM, Swearingen D, Di Spirito M, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006;46:785–791. McClaskey EM, Michalets EL. Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: Case report and review of the literature. Pharmacotherapy 2007;27:152–160. Onochie L. Personal communication, GlaxoSmithKline, April 23, 2008. TriCor (fenofibrate) tablets, prescribing information. North Chicago, IL: Abbott; 2004. Lopid (gemfibrozil) tablets, prescribing information. New York: Parke-Davis, Division of Pfizer, Inc.; 2003. Niaspan (niacin) extended-release tablets, prescribing information. Cranbury, NJ: Kos; 2007. Formulary dossier: Submission of clinical and economic data supporting formulary consideration of Omacor (omega-3 acid ethyl esters) capsules. Reliant; 2005. Drugstore.com. Available at: www.drugstore.com. Accessed May 17, 2008. Epocrates Rx Pro. Available at: www.epocrates.com. Accessed April 14, 2008. I NEW DRUGS continued from page 268 DRUG NEWS 32. loss quickly. Evicel has become important in hemostasis during liver and vascular procedures. The expansion of this indication to general surgery will bring the benefits of this product to more surgeons and their patients. Sources: www.pharmacyonesource.com; www.fda.gov; www.lifesciencesworld.com/news/views/58194 Public Health Notification: Stent Graft Monitoring Patients receiving endovascular grafts need continual surveillance. The notification focuses on the mortality risks associated with the AneuRx Stent Graft System, which is used to prevent abdominal aortic aneurysm (AAA) rupture. This is the only marketed device with long-term clinical follow-up of a significant number of patients at five years. Recommendations: 1. Clinicians should consider the information in the product labels and in the yearly clinical updates from Medtronic and other graft manufacturers when selecting treatments for patients with AAAs and in following previously treated patients. The clinical updates for three of the currently marketed AAA endovascular grafts can be found at these Web sites: www. endologix.com, www.goremedical.com, and www.medtronic. com. 2. Patients should be encouraged to comply with the followup recommendations in the product labeling. 3. The graft should be used only for patients who can be treated in accordance with the instructions and who meet the appropriate risk–benefit profile. Among the factors to consider are: 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. • the patient’s long-term AAA-related mortality, especially with AAA rupture. The risk of late AAA-related mortality associated with the AneuRx graft exceeds that associated with open surgery. • the experience of the institution or the physician. If open or endovascular surgery is performed in institutions or by physicians with little experience with this type of AAA repair, the mortality rate may be higher than average. • surgical risk factors. Elderly patients and those with cardiac, renal, pulmonary comorbidities may experience a higher-than-average mortality rate with open AAA resection. The rate can range from 2% in those with no risk factors to above 40% in those with several comorbidities. • the patient’s willingness to comply with the follow-up schedule for the graft. Source: www.fda.gov I COMING SOON TO P&T EDITORIAL: Career Advice David B. Nash, MD, MBA DRUG FORECAST: Etonogestrel (Implanon): A New Treatment Option for Contraception Dionne D. Maddox, PharmD, and Zahra A. Rahman, PharmD Vol. 33 No. 5 • May 2008 • P&T® 303 http://www.pharmacyonesource.com http://www.fda.gov http://www.lifesciencesworld.com/ http://www.endologix.com http://www.goremedical.com http://www.medtronic.com http://www.endologix.com http://www.medtronic.com http://Drugstore.com http://www.drugstore.com http://www.epocrates.com http://www.fda.gov
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.